Joel Charrow Selected Research

imiglucerase

1/2021	Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
9/2017	Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
2/2016	Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
7/2015	Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
5/2013	Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
3/2013	Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
2/2009	Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
2/2005	Individualization of long-term enzyme replacement therapy for Gaucher disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joel Charrow Research Topics

Disease

25	Gaucher Disease (Gaucher's Disease) 11/2023 - 08/2002
7	Fabry Disease (Fabry's Disease) 08/2016 - 05/2007
5	Achondroplasia 01/2024 - 01/2019
4	Pain (Aches) 01/2023 - 08/2002
4	Glycogen Storage Disease Type II (Pompe's Disease) 04/2015 - 04/2012
3	Anemia 02/2007 - 08/2002
2	Propionic Acidemia 05/2024 - 04/2015
2	Vomiting 01/2024 - 02/2007
2	Body Weight (Weight, Body) 01/2021 - 01/2019
2	Congenital Heart Defects (Congenital Heart Defect) 01/2020 - 04/2015
2	Schimke immunoosseous dysplasia 11/2016 - 09/2012
2	Stroke (Strokes) 01/2016 - 05/2015
2	Precocious Puberty 01/2016 - 03/2011
2	Neoplasms (Cancer) 01/2016 - 03/2011
2	Disease Progression 04/2012 - 02/2004
2	Isobutyryl-CoA dehydrogenase deficiency 03/2012 - 02/2007
2	Thrombocytopenia (Thrombopenia) 02/2004 - 08/2002
1	Erythema 01/2024
1	Injection Site Reaction 01/2024
1	Sudden Infant Death (SID) 01/2024
1	Gastroenteritis 01/2024
1	Skull Fractures (Skull Fracture) 01/2024
1	Absence Epilepsy (Childhood Absence Epilepsy) 01/2024
1	Autistic Disorder (Autism) 01/2024
1	Paramyxoviridae Infections (Parainfluenza) 01/2024
1	Otitis Media 01/2024
1	Pneumonia (Pneumonitis) 01/2024
1	Bronchiolitis 01/2024
1	Maple Syrup Urine Disease 04/2022
1	Partial Epilepsies (Epilepsy, Partial) 01/2020
1	Meningioma (Meningiomas) 01/2020
1	Microcephaly 01/2020
1	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 01/2020
1	Infantile Spasms (West Syndrome) 01/2020
1	Congenital Disorders of Glycosylation 01/2020
1	Facies 01/2020
1	Parkinson Disease (Parkinson's Disease) 01/2018
1	Late Onset Disorders 11/2017
1	Exocrine Pancreatic Insufficiency 01/2017
1	Pancytopenia 01/2017
1	Shwachman-Diamond Syndrome 01/2017
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2016
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2016
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2016
1	Hypotension (Low Blood Pressure) 12/2015
1	Bone Diseases (Bone Disease) 07/2015
1	Clinical Deterioration 07/2015
1	Osteonecrosis (Kienbock's Disease) 07/2015
1	Renal Insufficiency (Renal Failure) 05/2015
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 05/2015
1	Acidosis 04/2015
1	Spinal Cord Compression 01/2015
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 12/2013
1	Hyperplasia 09/2012

Drug/Important Bio-Agent (IBA)

8	imiglucerase FDA Link 01/2021 - 02/2005
6	eliglustatIBA 01/2023 - 02/2016
5	vosoritideIBA 01/2024 - 01/2019
5	Glucosylceramidase (Glucocerebrosidase)IBA 01/2018 - 02/2004
4	alglucerase FDA Link 01/2021 - 02/2009
4	GalactosidasesIBA 08/2016 - 12/2013
4	Glucosylceramides (Glucocerebrosides)IBA 02/2016 - 02/2004
3	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA 01/2024 - 01/2019
3	Hemoglobins (Hemoglobin)IBA 01/2021 - 08/2002
3	agalsidase beta FDA Link 01/2016 - 05/2007
3	globotriaosylceramide (globotriosylceramide)IBA 12/2015 - 05/2007
3	EnzymesIBA 07/2015 - 05/2007
2	sphingosyl beta-glucosideIBA 11/2023 - 02/2016
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2017
2	ChromatinIBA 11/2016 - 09/2012
2	AcidsIBA 02/2016 - 11/2012
2	GlucosidasesIBA 02/2016 - 11/2012
2	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 02/2011
2	Growth Hormone (Somatotropin)IBA 01/2016 - 03/2011
2	GlycosphingolipidsIBA 01/2016 - 01/2016
2	AntibodiesIBA 07/2015 - 04/2012
2	human GAA protein (Myozyme)FDA Link 04/2015 - 04/2012
1	Transaminases (Aminotransferases)IBA 05/2024
1	Biomarkers (Surrogate Marker)IBA 11/2023
1	Branched-Chain Amino AcidsIBA 04/2022
1	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 12/2021
1	Dihydrotachysterol (AT 10)IBA 01/2021
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2020
1	dolichyl-diphosphooligosaccharide - protein glycotransferase (oligosaccharyltransferase)IBA 01/2020
1	Factor VII (Proconvertin)IBA 01/2020
1	LipidsIBA 01/2020
1	Transferrin (beta 2 Transferrin)IBA 01/2020
1	Lysergic Acid Diethylamide (LSD)IBA 11/2017
1	DiamondIBA 01/2017
1	Investigational DrugsIBA 01/2017
1	migalastatIBA 08/2016
1	ceramide glucosyltransferaseIBA 02/2016
1	Insulin-Like PeptidesIBA 01/2016

Therapy/Procedure

18	Enzyme Replacement Therapy 01/2021 - 08/2002
16	Therapeutics 01/2024 - 05/2007
2	Enzyme Therapy 02/2009 - 02/2004
1	Time-to-Treatment 01/2016
1	Heart Transplantation (Grafting, Heart) 01/2016
1	Renal Dialysis (Hemodialysis) 01/2016
1	Cardiopulmonary Bypass (Heart-Lung Bypass) 04/2015
1	Anesthesia 01/2015